



CYBERKINETICS NAMED AMONG TOP 15 EMERGING LIFE SCIENCES COMPANIES OF 2004

FOXBOROUGH, Mass. – July 28, 2004 – Cyberkinetics, Inc. this morning announced that it has been selected as a member of FierceBiotech’s annual “The Fierce 15,” a list of the top emerging biotech and life sciences companies of 2004.

FierceBiotech Editor-in-chief John D. Carroll said that he chose Cyberkinetics for the potential he sees in its BrainGate™ product: “We believe that Cyberkinetics’ technology, which is designed to allow quadriplegic people to control computers and computer controlled devices using their thoughts, is based on solid science and backed up by a great management team. If it works, we believe that Cyberkinetics will have achieved an incredible feat.”

"FierceBiotech is recognized for its savvy coverage of trends and businesses in the biotech and life sciences industries," said Tim Surgenor, President and CEO of Cyberkinetics. "Being selected as a member of The Fierce 15 is an honor that recognizes Cyberkinetics’ potential to become a leader for the development of brain–computer interface devices."

Cyberkinetics’ BrainGate™ development program is an effort to develop an implantable system which can be used to provide an important advance in the level of independence for severely disabled people. The implant is designed to allow brain signals from the motor cortex to be collected, processed and analyzed, eventually producing an interface with a personal computer. In this way, the BrainGate™ System has the potential to afford people the opportunity to use the computer as a gateway to communicate and control assistive devices in their environment. Cyberkinetics is currently conducting a pilot clinical trial of the BrainGate™ Neural Interface System that can enroll up to five severely disabled people unable to use their arms and legs.

The Fierce 15 celebrates the spirit of being “fierce” – daring to be innovative and aggressive, even in an industry with a long time-to-market. The list of Fierce 15 companies is available in today’s issue of FierceBiotech and on the FierceBiotech web site at <http://www.fiercebiotech.com>.

FierceBiotech publishes a daily email briefing read by more than 31,000 executives in over 100 countries. Since its launch in March 2000, FierceBiotech has been recognized as a must-read source of news and intelligence for the biotech industry.

About Cyberkinetics, Inc.

Cyberkinetics is a leader in neurotechnology, an emerging field driven by advances in

neuroscience, computer science, and engineering that address the medical treatment of nervous system dysfunction. Cyberkinetics' first product, the BrainGate™ Neural Interface System, is designed to provide severely paralyzed patients with a long-term, direct brain-computer interface for the purpose of communication and control of a computer. Cyberkinetics' intellectual property features key technologies licensed from Brown University, the Massachusetts Institute of Technology, Emory University, and the University of Utah. Cyberkinetics is headquartered in Foxborough, Massachusetts and conducts engineering and research in Salt Lake City, Utah. More information is available at www.cyberkineticsinc.com.

About FierceBiotech

FierceBiotech is an internationally recognized email newsletter for the biotech industry. Every business day, more than 31,000 executives in over 100 countries rely on FierceBiotech for a quick, authoritative briefing on the day's top stories. It is published by FierceMarkets, Inc., a business publishing company based in Washington, DC.

Contacts:

Cyberkinetics, Inc.

Timothy Surgenor, President and CEO
Barbara Morse, Executive Assistant
Phone: 508.549.9981 Extension 100

Cyberkinetics Media Contact

MacDougall BioCommunications, Inc.
Kari Lampka
Phone: 508.647.0209
E-Mail: klampka@macbiocom.com

###